Ones To Watch News
Refine Search
Biotechnology
Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. 20 December 2024
Pharmaceutical
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional common stock in the company and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. 20 December 2024
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Biotechnology
STORM Therapeutics, a UK biotech discovering and developing small molecule therapies targeting RNA modification enzymes for oncology and other diseases, has announced the appointment of Gerald McMahon as president, chief executive and board director. 7 September 2022
Biotechnology
Nodus Oncology, a novel biotech company focused on developing first and best-in-class molecules inhibiting novel DNA damage response (DDR) targets, has launched with seed funding from Cumulus Oncology and announced a partnership with the Lead Discovery Center (LDC). 6 September 2022
Biotechnology
Dutch antibody-drug conjugate (ADC) specialist Synaffix and Germany’s Emergence Therapeutics today announced they have entered into a licensing agreement, providing Emergence access on a target-specific basis to Synaffix’ proprietary antibody drug conjugate (ADC) technologies comprising GlycoConnect, HydraSpace and SYNtecan E linker-payload. 6 September 2022
Biotechnology
UK-based biotech PhoreMost, which is dedicated to ‘Drugging the Undruggable’ disease targets, today announced it has entered into a multi-project target discovery collaboration with Swiss pharma giant Roche. 6 September 2022
Biotechnology
Chinese biotech Hutchmed is continuing its transition from a development stage company into a global commercial organization, according to analyst Trinity Delta. 5 September 2022
Pharmaceutical
A new chapter opens at privately-held Italian drugmaker Chiesi Farmaceutici as the 11-year tenure of chief executive Ugo Di Francesco, aged 62, comes to a close at the end of 2022. 5 September 2022
Biotechnology
French clinical-stage biotech Abivax closed up 5.6% at 8.45 euros on Friday, after it announced the successful completion of an oversubscribed 49.2 million euros ($49.3 million) financing with high-quality US and European biotech specialist investors. 3 September 2022
Biotechnology
Ori Biotech follows up financing with appointments and new facility. 2 September 2022
Biotechnology
Ocugen, a US biotech focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, has announced the appointment of Robert Hopkins as chief medical officer (CMO) and Arun Upadhyay as chief scientific officer (CSO). 1 September 2022
Biotechnology
Arcturus Therapeutics, a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, has announced that it has obtained an award for up to $63.2 million from the Biomedical Advanced Research and Development Authority (BARDA). 1 September 2022
Biotechnology
Danish biotech firm Ascendis Pharma saw its shares gain 2.6% to $ 2.22 late-morning, as it moved a step closer to bringing second commercial product to market. 31 August 2022
Biotechnology
Scandion Oncology, a Danish biotech developing medicines for treatment-resistant cancer, has announced that president and chief executive Bo Rode Hansen will leave his position with immediate effect by mutual agreement. 31 August 2022
Biotechnology
US biotech Curis saw its shares close down almost 10% at $1.01 yesterday, despite its announcement that the US Food and Drug Administration (FDA) has notified the company that it may resume enrollment of additional patients in the monotherapy phase of the TakeAim Leukemia study of emavusertib. 31 August 2022
Biotechnology
A biotechnology company aimed at creating a new class of medicines that precisely target disease biology, Vilya, has announced its launch with $50 million in committed Series A financing led by ARCH Venture Partners. 30 August 2022
Biotechnology
In just three months, Henlius’ heavily invested PD1 blockbuster Hansizhuang (serplulimab) rewarded the company with nearly 80 million renminbi ($11.6 million) since its launch in March 2022 in China to treat microsatellite instability-high (MSI-H). 27 August 2022
Biotechnology
Finch Therapeutics yesterday announced that it will regain full development and commercial rights to FIN-524 (previously known as TAK-524) and FIN-525 from Japanese pharma major Takeda Pharmaceutical. 26 August 2022
Biotechnology
Shares in liver and cardio-metabolic specialist 89bio were up 5% ahead of the opening bell on Friday, following positive Phase II results from the ENTRIGUE study. 26 August 2022
Biotechnology
US biotech BioMarin Pharmaceutical yesterday announced that the European Commission (EC) has granted conditional marketing authorization (CMA) to Roctavian (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A (congenital Factor VIII deficiency) in adult patients without a history of Factor VIII inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (AAV5). 25 August 2022
Biotechnology
Zelluna Immunotherapy, a Norwegian company developing allogeneic T Cell Receptor Natural Killer (TCR-NK) cells for the treatment of cancer, has announced an investment from Takeda Ventures. 25 August 2022
Biotechnology
Privately-held Gensaic, a company that seeks to reimagine gene therapy, announced today that it has entered into a strategic collaboration agreement with US neurological diseases specialist Ovid Therapeutics. 24 August 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze